Testing a new three-drug combination for advanced pancreatic cancer

Plain-English translation of NCT07595172 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing whether NALIRIFOX combined with two other medications called adebrelimab and PULSAR can help treat advanced pancreatic cancer. The goal is to see if this three-drug combination works better than current standard treatments for people whose cancer cannot be removed by surgery or has spread to other parts of the body. Researchers want to learn if this new approach can slow the cancer's growth and help people live longer.

Pancreatic cancer is very difficult to treat, especially when it has spread or cannot be surgically removed. Current treatments have limited effectiveness, so doctors are looking for better options to give patients more hope and better outcomes.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with pancreatic ductal adenocarcinoma (pancreatic cancer) that has not been treated before
your cancer cannot be surgically removed or has spread to other parts of your body
you are in good enough health to receive the treatment, with adequate organ function
you are willing and able to follow the study plan and attend all appointments

You likely don't qualify if…

you are pregnant, breastfeeding, or unwilling to use contraception during the study
you have had another cancer in the past 5 years (with some exceptions)
you have active bleeding problems or are currently taking blood-thinning medications
you have severe lung disease or evidence of lung scarring
you have had major surgery within the past 4 weeks

What participation looks like

You would receive the three-medication combination as your first treatment for pancreatic cancer. The study includes radiation planning and imaging scans to plan your care. You'll need to attend regular appointments for treatment, blood tests, and monitoring to see how well the medication is working and to watch for any side effects. The exact length of the study would be discussed with your doctor, but participation requires your commitment to follow the treatment plan and attend all scheduled visits.

AI-generated summary from trial data · Jun 10, 2026 · Not medical advice

Trial locations(1 site)

China

West China Hospital, Sichuan University, Chengdu, Sichuan